Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Celgene Corp (CELG)

Celgene Corp (CELG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 77,035,920
  • Shares Outstanding, K 711,714
  • Annual Sales, $ 15,281 M
  • Annual Income, $ 4,046 M
  • 60-Month Beta 1.41
  • Price/Sales 5.04
  • Price/Cash Flow 12.20
  • Price/Book 6.37
Trade CELG with:
  • Price/Earnings ttm 10.99
  • Earnings Per Share ttm 9.84
  • Most Recent Earnings $2.99 on 10/31/19
  • Latest Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 2.88
  • Number of Estimates 2
  • High Estimate 3.04
  • Low Estimate 2.72
  • Prior Year 2.20
  • Growth Rate Est. (year over year) +30.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
102.40 +5.70%
on 10/21/19
110.70 -2.22%
on 11/13/19
+5.29 (+5.14%)
since 10/18/19
3-Month
93.41 +15.88%
on 08/23/19
110.70 -2.22%
on 11/13/19
+12.98 (+13.63%)
since 08/20/19
52-Week
58.59 +84.74%
on 12/26/18
110.70 -2.22%
on 11/13/19
+41.49 (+62.16%)
since 11/20/18

Most Recent Stories

More News
Inside Gilead's Lackluster $7.2 Billion Q4 Earnings

Why are investors unenthused with the biotech giant's earnings report?

GILD : 73.26 (-0.58%)
JUNO : 86.96 (+0.10%)
CELG : 108.24 (+0.10%)
BMY : 51.59 (-1.43%)
GSK.LN : 1,660.800 (+0.68%)
PFE : 27.72 (-0.79%)
RCUS : 17.22 (-9.27%)
BRISTOL MYERS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Bristol-Myers Squibb Company - BMY

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 6, 2021 to file lead plaintiff applications...

BMY : 51.59 (-1.43%)
CELG : 108.24 (+0.10%)
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Bristol-Myers Squibb Company (“Bristol-Myers” or “the Company”) (NYSE:...

BMY : 51.59 (-1.43%)
CELG : 108.24 (+0.10%)
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Bristol-Myers Squibb Company (“Bristol-Myers” or “the Company”) (NYSE:...

BMY : 51.59 (-1.43%)
CELG : 108.24 (+0.10%)
BRISTOL-MYERS CVR INVESTORS: December 6, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser

The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in the class action litigation that has been filed against...

BMY : 51.59 (-1.43%)
CELG : 108.24 (+0.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Their portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID,...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 109.35
1st Resistance Point 108.80
Last Price 108.24
1st Support Level 107.48
2nd Support Level 106.71
3rd Support Level N/A

See More

52-Week High 110.70
Last Price 108.24
Fibonacci 61.8% 90.79
Fibonacci 50% 84.64
Fibonacci 38.2% 78.50
52-Week Low 58.59

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar